You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The proposed order is intended to give patients more timely access to the tests by moving them from Class III to Class II and providing special controls.
Revenue growth in Q2 was driven by strong sales of the company's Panorama noninvasive prenatal test and Horizon carrier screening test.
The viral assay, developed with Sentinel Diagnostics, improves the ability to monitor viral loads in critical organ transplant populations for the clinical management of infection.
The company reported $41.8 million in total revenues for the quarter and said testing services revenues rose 41 percent year over year.
The investment bank said CareDx's products are gaining traction and that the stock is positioned for 20 percent to 30 percent growth over the next few years.
CareDx, which focuses on transplant medicine, said it intends to use the proceeds from the offering for working capital and general corporate purposes.
The company, which launched the technology in September 2019, said in its Q4 earnings release that it received high marks from beta testers.
The agreement marks Veracyte's first deal to expand the testing menu on the nCounter instrument since it acquired the rights to the platform from NanoString in December.
Noridian is also developing a generic policy for donor-derived cfDNA tests that will include several commercially available tests, Natera said.
Natera reported $94 million in revenues for the quarter, up from $66.8 million a year ago and beating analysts' consensus estimate of $85 million.